Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072214 · ClinicalTrials.gov registry record · Phase 1
A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers
A Phase 1 study of Macular Degeneration, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01072214: Completed Phase 1 study of Macular Degeneration, sponsored by GlaxoSmithKline.
NCT01072214 is a Phase 1 study of Macular Degeneration that has completed, run by GlaxoSmithKline. The registered enrollment target is 37 participants, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01072214, a Phase 1 study of Macular Degeneration, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to determine the safety and tolerability of pazopanib eye drops. The study will also determine how the drug is absorbed and metabolized over time. Repeat doses of eye drops will be administered to healthy adult volunteers over a 14-day period with one additional dose given on the 15th day of the session. Three groups of subjects may receive either active drug or placebo (drops without drug). The first group of subjects will receive a maximum of 1.6mg of pazopanib or placebo. The dose of drug to be given to the next two groups will be determined based on the results of the first group of subjects. The last group of subjects will be of Japanese descent.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG pazopanib
Study Locations (1)
California
- GSK Investigational Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-03-09 |
| Est. Completion | 2010-06-28 |
| Phase | Phase 1 |
What the finished NCT01072214 record still lists
NCT01072214 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01072214 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01072214 about?
NCT01072214 is a clinical study titled "A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers". A study to determine the safety and tolerability of pazopanib eye drops. The study will also determine how the drug is absorbed and metabolized over time. Repeat doses of eye drops will be administered to healthy adult volunteers over a 14-day period with one additional dose given on the 15th day of...
What is the current status of trial NCT01072214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2010-03-09. Estimated completion is 2010-06-28.
What conditions does trial NCT01072214 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT01072214?
The interventions under investigation include: Placebo (DRUG), pazopanib (DRUG).
Who is sponsoring clinical trial NCT01072214?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01072214 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01072214's enrollment target sits among peer trials
37 18th of 26 higher than 9 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
-
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
COMPLETED · Phase 1
-
Identification and Treatment of Feeder Vessels in Macular Degeneration
COMPLETED · Phase 1
-
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
COMPLETED · Phase 1
-
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
COMPLETED · Phase 1
-
Cooling Anesthesia for Intravitreal Injection
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI